Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Yerushalmi

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 5, 2016
Malignancy associated SIADH: Characterization and clinical implicationsH Goldvaser, B Rozen-Zvi, R Yerushalmi, et al.
Experimental Oncology|August 21, 2007
Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitroR Yerushalmi, J Nordenberg, E Beery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?R Yerushalmi, S Tyldesley, R Woods, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2011
Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcomeR Yerushalmi, S Tyldesley, H Kennecke, et al.
Leukemia|August 11, 2007
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfanA Shimoni, I Hardan, N Shem-Tov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective studyR Yerushalmi, M R Kramer, S Rizel, et al.
The British Journal of Radiology|December 1, 2011
CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tractA Shimoni, U Rimon, M Hertz, et al.
Leukemia|November 25, 2005
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensityA Shimoni, I Hardan, N Shem-Tov, et al.
Journal of Neuro-Oncology|June 13, 2013
Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosisS Yust-Katz, P Garciarena, D Liu, et al.
Leukemia|October 18, 2012
Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reducedA Shimoni, N Shem-Tov, A Chetrit, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Acta Oncologica (Stockholm, Sweden)|May 5, 2016
Malignancy associated SIADH: Characterization and clinical implicationsH Goldvaser, B Rozen-Zvi, R Yerushalmi, et al.
Experimental Oncology|August 21, 2007
Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitroR Yerushalmi, J Nordenberg, E Beery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?R Yerushalmi, S Tyldesley, R Woods, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2011
Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcomeR Yerushalmi, S Tyldesley, H Kennecke, et al.
Leukemia|August 11, 2007
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfanA Shimoni, I Hardan, N Shem-Tov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective studyR Yerushalmi, M R Kramer, S Rizel, et al.
The British Journal of Radiology|December 1, 2011
CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tractA Shimoni, U Rimon, M Hertz, et al.
Leukemia|November 25, 2005
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensityA Shimoni, I Hardan, N Shem-Tov, et al.
Journal of Neuro-Oncology|June 13, 2013
Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosisS Yust-Katz, P Garciarena, D Liu, et al.
Leukemia|October 18, 2012
Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reducedA Shimoni, N Shem-Tov, A Chetrit, et al.
Pageof 4